Alnylam Pharmaceuticals (BSP:A1LN34) Accounts Payable & Accrued Expense : R$3,167 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Alnylam Pharmaceuticals Accounts Payable & Accrued Expense?

Alnylam Pharmaceuticals's quarterly accounts payable & accrued expense increased from Jun. 2023 (R$3,195 Mil) to Sep. 2023 (R$3,886 Mil) but then declined from Sep. 2023 (R$3,886 Mil) to Dec. 2023 (R$3,167 Mil).

Alnylam Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2021 (R$2,121 Mil) to Dec. 2022 (R$2,690 Mil) and increased from Dec. 2022 (R$2,690 Mil) to Dec. 2023 (R$3,167 Mil).

Alnylam Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for Alnylam Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Accounts Payable & Accrued Expense Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

733.81

1,597.13

2,120.68

2,690.18

3,167.05

Alnylam Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															2,690.18	2,973.26	3,195.07	3,886.43	3,167.05

Alnylam Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Alnylam Pharmaceuticals (BSP:A1LN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (BSP:A1LN34) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (BSP:A1LN34) Headlines

No Headlines